Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema

Main inclusion criteria: * Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months. * Disease severity graded as moderate to severe at screening and baseline according to Investigator's Global Assessment for chronic hand eczema (IGA-CHE) (i.e. an IGA-CHE score of 3 or 4). * Hand Eczema Symptom Diary (HESD) itch score (weekly average) of ≥4 points at baseline. * Participants who have a documented recent history of inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks). * Participants adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens. Main exclusion criteria: * Concurrent skin diseases on the hands, e.g. tinea manuum. * Active atopic dermatitis requiring medical treatment in regions other than the hands and feet. * Active psoriasis on any part of the body. * Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body. * Clinically significant infection on the hands. * Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, or corticosteroids within 28 days prior to baseline. * Use of tanning beds, phototherapy, or bleach baths on the hands within 28 days prior to baseline. * Previous or current treatment with Janus kinase (JAK) inhibitors (incl…